The Phase 3 study investigating tofacitinib for patients with recurrent glioblastoma (NCT05326464) reached its primary completion on June 16, 2025. This trial enrolled 17 participants to examine the effects of the drug in this patient population.
Background
This study, titled "Tofacitinib in Recurrent GBM Patients," aims to examine the effects of tofacitinib in patients diagnosed with recurrent Glioblastoma.
Trial design
The study (NCT05326464) is a Phase 3 trial that enrolled 17 participants. It investigates tofacitinib 10mg in patients with Glioblastoma. The primary purpose is to examine the effects of tofacitinib in patients with recurrent Glioblastoma.
What this means
The primary completion of this Phase 3 trial for tofacitinib in recurrent glioblastoma marks a significant step in the study's progression. While specific efficacy or safety data are not yet available, reaching this milestone indicates that the primary data collection phase for the study's main objectives has concluded. Future updates will likely include the release of results, which will be crucial for understanding the potential role of tofacitinib in treating this aggressive form of brain cancer.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05326464, titled "Tofacitinib in Recurrent GBM Patients," was noted on June 16, 2025, on clinicaltrials.gov.